Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy-Reference-Cited by-同舟云学术

Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy

Published:2020-06-24 Issue:549 Volume:12 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Waite Janelle C.¹^ORCID,Wang Bei¹^ORCID,Haber Lauric¹^ORCID,Hermann Aynur¹^ORCID,Ullman Erica¹^ORCID,Ye Xuan¹^ORCID,Dudgeon Drew¹^ORCID,Slim Rabih¹,Ajithdoss Dharani K.¹,Godin Stephen J.¹,Ramos Ilyssa¹,Wu Qi¹^ORCID,Oswald Erin¹,Poon Patrick¹^ORCID,Golubov Jacquelynn¹^ORCID,Grote Devon¹^ORCID,Stella Jennifer¹,Pawashe Arpita¹^ORCID,Finney Jennifer¹^ORCID,Herlihy Evan¹^ORCID,Ahmed Hassan¹^ORCID,Kamat Vishal¹,Dorvilliers Amanda¹^ORCID,Navarro Elizabeth¹,Xiao Jenny¹^ORCID,Kim Julie¹^ORCID,Yang Shao Ning¹,Warsaw Jacqueline¹,Lett Clarissa¹^ORCID,Canova Lauren¹,Schulenburg Teresa¹,Foster Randi¹,Krueger Pamela¹^ORCID,Garnova Elena¹^ORCID,Rafique Ashique¹^ORCID,Babb Robert¹,Chen Gang¹,Stokes Oristian Nicole¹^ORCID,Siao Chia-Jen¹^ORCID,Daly Christopher¹^ORCID,Gurer Cagan¹,Martin Joel¹^ORCID,Macdonald Lynn¹^ORCID,MacDonald Douglas¹^ORCID,Poueymirou William¹^ORCID,Smith Eric¹,Lowy Israel¹,Thurston Gavin¹,Olson William¹^ORCID,Lin John C.¹,Sleeman Matthew A.¹^ORCID,Yancopoulos George D.¹,Murphy Andrew J.¹^ORCID,Skokos Dimitris¹^ORCID

Affiliation:

1. Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA.

Abstract

Antibodies cross-linking the CD28 costimulatory pathway and a target antigen on tumors potentiate the effects of checkpoint immunotherapy.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference77 articles.

1. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

2. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

3. Immune Checkpoint Blockade in Cancer Therapy